Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants

• 2023

  Log in to bookmark this resource.

  Log in
• Simon Drysdale; Katrina Cathie; Florence Flamein; Markus Knuf; Andrea Collins; Helen Hill
PMID: 38157500DOI: https://doi.org/10.1056/NEJMoa2309189

---

Access Resources

• Journal ArticleEN
• Ask aRCie About This Resource

About

This article discusses a study on nirsevimab, a monoclonal antibody used to prevent hospitalizations due to RSV in infants. It was tested on 8,058 infants in France, Germany, and the UK. The results showed that nirsevimab reduced RSV-related hospitalizations by 83.2% compared to standard care. It also decreased severe cases needing oxygen support by 75.7%. The study found no major safety concerns with nirsevimab use and suggests it could help reduce the burden of RSV hospitalizations among infants during their first season of exposure to the virus.

---

Tags

Focus Area: Infectious Disease

Keywords: France; Germany; Hospitalization; Infant; Respiratory Syncytial Virus Infections; Respiratory Tract Infections; United Kingdom; Respiratory Syncytial Virus, Human; Antibodies, Monoclonal, Humanized

Emergency Management Stage: Preparedness (Prevention / Protection)

Audience: Physicians

Format: Journal Article

Media Type: Website

Institutions: St. George's University Hospitals NHS Foundation Trust; University Hospital Southampton NHS Foundation Trust; Liverpool University Hospitals Foundation NHS Trust; Sanofi; Université Paris-Saclay; Assistance Publique - Hôpitaux de Paris (AP-HP)

Institution Types: Healthcare; Healthcare; Other; Healthcare; Academic; Healthcare

Language: English

Bundles: Nirsevimab Library

---

More like this

Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants 2023 · St. George's University Hospitals NHS Foundation Trust, University Hospital Southampton NHS Foundation Trust, Liverpool University Hospitals Foundation NHS Trust, Sanofi, Université Paris-Saclay, Assistance Publique - Hôpitaux de Paris (AP-HP) Universal Infant Immunisation Against Respiratory Syncytial Virus and European Inequalities: The Pandemics Lesson Has Not Been Learnt 2023 · Hôpital Antoine-Béclère AP-HP, Université Paris-Saclay, American College of Emergency Physicians, Hospital General Universitario Gregorio Marañón, St. Marien Children's Hospital, University Medical Centre Utrecht, Respiratory Syncytial Virus NETwork (ReSViNET) Foundation, University Hospital of Padova Going Viral: Adapting to Pediatric Surge During the H1N1 Pandemic 2013 · Boston Children's Hospital, Harvard Medical School, Children's National Hospital, George Washington University, University of Michigan, University of Pittsburgh, Children's Hospital Los Angeles, University of Southern California, Yale University

---

The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

---